•Novel
DHODH inhibitors developed
•HOSU-3
induces cell death and differentiation primary AML blasts
•HOSU-3
exhibits sustained, dose linear oral bioavailability in mice
•In
vitro ADME was completed with no major concerns
•Established
in vivo efficacy of HOSU-3 in a xenograft model
•Next
milestones:
additional assessment of in vivo efficacy & new analogs development